View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 24, 2021updated 11 Jul 2022 9:48am

Oncotelic’s OT-101 meets safety and efficacy goals in Covid-19 trial

In the trial, overall survival rose by three times for critical patients treated with OT-101 compared to placebo.

Oncotelic Therapeutics has reported that its lead drug candidate, OT-101, met the safety and efficacy goals of Phase II C001 clinical trial in individuals with severe Covid-19 who are admitted to the hospital.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An anti-TGF-β ribonucleic acid therapy, OT-101 demonstrated single-agent activity in individuals with relapsed/refractory cancer in various trials.

As part of the immune evasion mechanisms, tumour cells and the SARS-CoV-2 virus produce TGF- β.

As a result, suppressing TGF- β using OT-101 could have an effect on both cancer and Covid-19.

As compared to standard antiviral therapies and vaccines, OT-101 potentially works against several respiratory viruses by acting on the host protein.

The randomised, placebo-controlled, double-blind, multicentre trial evaluated OT-101 in combination with the standard of care (SOC) as against placebo plus SOC in a total of 32 subjects.

SOC comprises dexamethasone, a drug claimed to boost outcomes in individuals with severe Covid-19.

Findings showed that OT-101 met the safety goals of the trial, indicating that the TGF-β inhibitor therapy was safe to use in people with Covid-19, including those with severe/critical disease.

Furthermore, the mortality was 4.5% in the subjects treated with OT-101 compared to 20% in the placebo arm on day seven, meeting the efficacy signals.

On day seven, 89% of the subjects who received OT-101 had more than 96% reduction in viral load as against 67% in the placebo group.

Overall survival rose by three times for critical patients treated with OT-101, reported at 14 days for OT-101 versus four for those who received placebo.

Oncotelic CEO and chairman Dr Vuong Trieu said: “It is gratifying that the TGF-β concept that we put forward has now been validated.

“The data form the basis for further development of OT-101 as a viable treatment for severe respiratory viral infections, including flu and Covid-19.”

In August 2019, Mateon, which formed due to a reverse merger with Oncotelic, took over the computer and artificial intelligence company PointR Data.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology